Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corn oil QHC approved

This article was originally published in The Tan Sheet

Executive Summary

Scientific evidence supports a substance/disease relationship linking corn oil consumption to a reduced risk of coronary heart disease, but FDA "believes that the scientific evidence represents a very low level of comfort among qualified scientists that the claimed relationship is scientifically valid," the agency says in a qualified health claim approval March 26. Therefore, enforcement discretion will be exercised for label statements that provide a non-misleading description of the strength of the scientific evidence, such as "very limited and preliminary scientific evidence suggests," FDA notes. The Wood Burditt Group submitted a petition in April 2006 seeking approval of claims such as "substituting corn oil for solid fats may reduce your risk of heart disease." The agency points out in its approval letter that among the intervention studies submitted to support the claim, three did not measure a validated surrogate endpoint of CHD, 17 did not include a control group consuming saturated fatty acids, six did not perform statistical analysis between the intervention and control groups and 17 had a duration of intervention that was too short (less than three weeks)...

You may also be interested in...



US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques

The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.

Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel